GlassScriptPhysician profile
Mark Joseph Gros
NPI 1881697571
$1,332.76
in general payments reported to CMS, 2019-2025
27 companies · $141 in 2025
The $141 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $338 · 2020: $116 · 2021: $233 · 2022: $256 · 2023: $166 · 2024: $83.71 · 2025: $141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $391.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $390.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $210.02 | 2019-2025 | |
| Organon LLC | $121.00 | 2021-2025 | Jada System, Nexplanon |
| Merck Sharp & Dohme LLC | $102.95 | 2019-2020 | |
| Coopersurgical, INC. | $88.15 | 2019-2025 | Paragard T 380a, Paragard T 380a |
| Exeltis, USA INC. | $88.13 | 2021-2025 | Slynd |
| Agile Therapeutics, INC. | $80.37 | 2021-2023 | Twirla |
| Bayer Healthcare Pharmaceuticals INC. | $80.27 | 2019-2020 | |
| Medtronic, INC. | $74.86 | 2022-2023 | Truclear |
| Biogen, INC. | $61.46 | 2024-2025 | Zurzuvae |
| Evofem Biosciences, INC. | $45.21 | 2021-2022 | |
| Novo Nordisk INC | $37.69 | 2021-2022 | |
| Allergan, INC. | $35.56 | 2020 | |
| Coloplast Corp | $27.25 | 2021-2023 | Altis |
| Duchesnay USA Incorporated | $27.05 | 2019 | |
| Therapeuticsmd, INC. | $25.87 | 2020-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covidien LP | $25.00 | 2019 | |
| Sumitomo Pharma America, INC. | $24.60 | 2024 | Gemtesa |
| Aspira Women'S Health INC | $23.05 | 2022 | |
| Bard Access Systems, INC. | $20.49 | 2019 | |
| Astellas Pharma US INC | $20.29 | 2019-2024 | Veozah |
| Minerva Surgical, INC | $19.58 | 2025 | |
| Smith+Nephew, INC. | $18.61 | 2019 | |
| Molnlycke Health Care US, LLC | $18.01 | 2024 | Mepilex Border Post-Op, Mepilex Border Ag |
| Myovant Sciences INC. | $15.29 | 2022 | |
| Hologic Sales and Service, LLC | $14.36 | 2019 | |
| Axonics, INC. | $13.96 | 2022 | |
| Pfizer INC. | $13.68 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Gros listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.